Autoimmune hemolytic anemia secondary prevention

Jump to navigation Jump to search

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia secondary prevention

CDC on Autoimmune hemolytic anemia secondary prevention

Autoimmune hemolytic anemia secondary prevention in the news

Blogs on Autoimmune hemolytic anemia secondary prevention

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

There is no significant role for secondary prevention of autoimmune hemolytic anemia.

Secondary Prevention

  • There is no role for secondary prevention of autoimmune hemolytic anemia.
  • However, in patients at risk for hemolytic anemia who are suspected of having active hemolysis, screening for active hemolysis can be done via assessment of complete blood count (CBC), lactate dehydrogenase (LDH), total bilirubin, and reticulocyte count.[1]

References

  1. Zanella A, Barcellini W (2014). "Treatment of autoimmune hemolytic anemias". Haematologica. 99 (10): 1547–54. doi:10.3324/haematol.2014.114561. PMC 4181250. PMID 25271314.

Template:WikiDoc Sources